富蘭克林坦伯頓全球投資系列-生技領航基金美元A(acc)股
38.34美元0.83(2.12%)
2025/01/10更新
績效 / 1月8.43%
3月11.6%
1年2.39%
晨星評等 - 1.現金3.47%
- 2.股票12.27%
- 3.債券0.00%
- 4.其他84.26%
- 1.美國83.78%
- 2.歐元區4.15%
- 3.英國4.10%
- 4.歐洲不包含歐元區3.02%
- 5.加拿大0.92%
- 1.Amgen Inc6.05%
- 2.Vertex Pharmaceuticals Inc5.82%
- 3.Gilead Sciences Inc5.64%
- 4.Regeneron Pharmaceuticals Inc5.57%
- 5.Intra-Cellular Therapies Inc3.73%
- 6.argenx SE ADR3.51%
- 7.Jazz Pharmaceuticals PLC3.36%
- 8.Neurocrine Biosciences Inc2.86%
- 9.AstraZeneca PLC ADR2.83%
- 10.Merus NV2.65%
- 1.現金3.47%
- 2.股票12.27%
- 3.債券0.00%
- 4.其他84.26%
- 1.美國83.78%
- 2.歐元區4.15%
- 3.英國4.10%
- 4.歐洲不包含歐元區3.02%
- 5.加拿大0.92%
- 1.Amgen Inc6.05%
- 2.Vertex Pharmaceuticals Inc5.82%
- 3.Gilead Sciences Inc5.64%
- 4.Regeneron Pharmaceuticals Inc5.57%
- 5.Intra-Cellular Therapies Inc3.73%
- 6.argenx SE ADR3.51%
- 7.Jazz Pharmaceuticals PLC3.36%
- 8.Neurocrine Biosciences Inc2.86%
- 9.AstraZeneca PLC ADR2.83%
- 10.Merus NV2.65%